Diagnostics & medtech

Read the thirty-odd subjects of this cluster together — biosensors, sequencing, imaging, organ-on-chip, the consumer formats — and three arguments keep reappearing. Hold them before starting anywhere.

Every method lives or dies by one bounding quantity. Not by its feature list: by the affinity window of its binding chemistry, the sequencing-error rate standing against the variant frequency it claims to call, the Poisson floor under single-molecule counting, the stability window between collection and analysis, the prevalence term inside every screening calculation. The pages here name that quantity for each subject, because it is where the method’s honest limits and its engineering frontier both live — diagnostics biosensors sets out the transduction vocabulary the others reuse.

Measurement is a negotiation with the body’s own noise. The interesting designs do not silence the noise; they route around it. Synthetic reporters turn pathology itself into the signal. Liquid biopsy reads tumour fragments the immune system has already filtered. Wearables trade absolute accuracy for continuous context and recover decisions from the trend. Organoids and chips replace the noise of a whole animal with controlled, legible physics. In each case the design question is not “how sensitive” but “what does the body do to the measurement” — and the answer is where device coatings, biobanks and specimen handling earn their keep.

The field’s direction is temporal. Diagnosis began as an answer after the fact — pathology confirmed, resistance measured, disease staged. Its newest chapters move the same measurements earlier: antibiotic susceptibility in hours instead of days, minimal residual disease instead of relapse, a genomic surveillance signal instead of an outbreak. What has changed is not the chemistry but the temporal structure of the decision, from answer-after-the-fact to answer-in-time-to-use.

Start with the rank-one page if you want the measurement spine, or anywhere else — each page links to whichever of these three arguments it demonstrates.

How biosensors measure Why recognition and transduction separate cleanly, how affinity constants set the measurable concentration window, what defines a detection limit statistically, and the Poisson floor that keeps shrinking sample volumes honest.
Molecular diagnostics at the point of care Why exponential copying needs temperature cycling, how isothermal chemistries cheat that requirement enzymatically, what actually fills most of the cartridge's volume, and which false answers a sealed system still cannot prevent.
CRISPR diagnostics How collateral cleavage converts one guided recognition event into millions of destroyed reporter molecules, why the guide RNA alone reprograms the assay, where the famous attomolar sensitivities actually come from, and which steps stay quietly indispensable.
Liquid biopsy and circulating tumour DNA What cell-free DNA is and why its length betrays tumour origin, how sequencing error itself becomes the main obstacle, what molecular barcodes and partitioned reactions do about it, and why residual-disease monitoring beats imaging on timing alone.
Multi-cancer early detection Why false positives outnumber true ones however good the assay sounds, why methylation patterns rather than mutations carry both detection and localisation, what a machine-learning classifier can and cannot be trusted to have learned, and who overdiagnosis strikes.
Direct-to-consumer genetic testing How genotyping arrays differ from sequencing in what they can physically see, why polygenic scores speak in percentiles rather than fates, where ancestry-based score portability breaks, and which three kinds of answer a consumer report actually carries.
Companion diagnostics: tissue assays for drug eligibility How antibody staining turns catalysis into measurement, what counting chromosome probes settles that staining cannot, why every cut-off belongs to the drug trial that validated it, and where tumour heterogeneity defeats any single biopsy.
Microbiome diagnostic panels How 16S barcodes differ from shotgun sequencing in depth and honesty, why relative-abundance data manufacture fake replacements, which clinical uses survive confounding intact, and where the line sits between pathogen detection and wellness storytelling.
Epigenetic clocks How bisulfite conversion makes methylation readable at scale, why a few hundred CpG sites suffice where eighty-five thousand wouldn't be believed, how first-, second- and pace-of-aging clocks differ in their training targets, and where prediction silently fails to become cause.
Multi-omics profiling in precision oncology Which questions each molecular layer answers uniquely, why RNA evidence outranks DNA inference for rearrangements, how evidence tiers separate proven pairings from speculation, and why variant-of-unknown-significance remains oncology's largest output category.
Genomic pathogen surveillance How mutation clocks turn pairwise sequence differences into transmission maps, what portable field sequencing changes about outbreak tempo, why sampling design is the true sensor, and the three ways genomic surveillance quietly misleads.
AI interpretation of tissue slides How multiple-instance learning trains on slide-level verdicts alone, why self-supervised pretraining replaced scarce expert annotation, which tasks suit search rather than judgement, and what scanner-to-scanner drift shares with batch effects anywhere else.
AI reading of OCT eye scans How low-coherence interference resolves retinal layers at micrometres, why ophthalmology hosted the first autonomous AI diagnosis in medicine, what the ungradable-image escape valve protects, and which eye diseases resist single-snapshot judgement.
Retinal biomarkers for neurodegeneration What makes retinal layers defensible stand-ins for neural loss, how three signal families — structural thickness, spectral signatures, amyloid fluorescence — attempt the translation, and which statistical bargains the proxy still owes before clinical use.
Wearable biodiagnostics How enzymatic electrochemistry reads interstitial glucose and why its few-minute lag matters, what sweat genuinely reflects versus approximates, which arrhythmias two-week patches unmask, why cuffless blood pressure remains a calibrated trend rather than a measurement, and how continuous data reorganises clinical thinking.
Implantable biosensors How the foreign-body response dictates both signal quality and service life, why a glowing polymer without internal power lasts a year where enzyme electrodes cannot, what makes catching intermittent arrhythmia a coverage-probability calculation, and which bills surgery attaches.
Ingestible biosensors and smart pills How camera capsules colonised the small bowel that endoscopes could not reach, why reading fifty thousand frames became the real bottleneck, what magnetic piloting adds for the stomach, and how acid-triggered transmitters turned adherence into data.
Breathomics Which volatiles travel from blood to alveolar air and why, how proton-transfer mass spectrometry reads traces in real time, why multi-compound 'breathprint' classifiers keep failing cross-centre reproduction, and which three breath tests already hold clinical ground.
Breath-based metabolic monitoring Why blood sugar is physically invisible in alveolar air while ketones blaze through it, which clinical uses acetone genuinely supports, what oxide sensors mistake for it, and the equivalence bar any direct glucose-from-breath claim must still clear.
Tear-fluid diagnostics How hyperosmolarity anchors the dry-eye diagnosis, what matrix-metalloproteinase and IgE tests settle at point of care, why basal versus reflex tearing changes the answer, and where 'biopsy' branding outruns what the fluid can honestly say about the body.
Synthetic biomarkers Why enzyme activity outperforms molecular abundance as a readout, how protease-cleaved barcode nanosensors turn urine into a disease census, how designed probes rescue breath analysis from background noise, and which safety and causality bills intentional dosing must pay.
Home blood-analysis kits How capillary blood differs chemically from venous, why shrinking samples raises detection floors analyte by analyte, what dried-spot heritage lends microsampling, and which parts of the consumer menu stand on firm ground versus marketing.
Wastewater-based epidemiology Why aggregate shedding beats individual testing for early warning, how concentration chemistry and a pepper-virus normaliser tame raw sewage, what makes droplet digital PCR the right counter in a filthy matrix, and what the method structurally cannot tell anyone.
One Health monitoring: zoonoses and resistance How resistance genes travel between reservoirs faster than pathogens do, what shotgun sequencing plus a resistance-gene database actually measures — and what it cannot, why farm-lake-abattoir interfaces hold the lead time, and why proving averted outbreaks is inherently hard.
Intraoperative tissue identification How metabolic targeting makes gliomas fluoresce under blue light, what Raman scattering and surgical smoke reveal about tissue chemistry, why decision latency and sampling fraction — not image quality — are the real constraints, and where fluorescence lies.
Rapid antibiotic-susceptibility testing Why empiric therapy is a deadline bet that selects resistance, how phenotypic acceleration reads morphology before visible growth, what magnetic-resonance gene detection adds and foregoes, and the stewardship arithmetic that makes hours count.
Organoids & organ-on-chip The science of self-organizing organoids and perfused organ-on-chip devices: developmental programs that run without a body, the physics of shear and cyclic strain, TEER as a barrier readout, and the maturation, variability and material limits that keep the field honest.
Biocompatible coatings for medical devices The science of device coatings: hydration-shell lubrication, crosslink density as the UV-cure control knob, protein adsorption as the real hemocompatibility problem, and the durability-versus-biology trade that every formulation strikes.
Personalized diagnostics The science of personalization in diagnostics: pharmacokinetic genotyping, HLA-typed immune idiosyncrasy, driver-versus-passenger tumour logic, and the statistical ceiling — small per-variant effects and ancestry-biased reference panels — that keeps personalization probabilistic.
Next-gen bio-forensics The science behind sequencing-based forensics: why STR matching could only confirm, what allele-frequency structure lets SNP profiles predict, how identity-by-descent search finds relatives no database contains, and where the statistical and ethical limits sit.
Biobanks & human population samples The science of long-term biospecimen storage: preanalytical decay and stability windows, the formalin trade between morphology and nucleic-acid integrity, vitrification versus slow-freeze ice damage, lyophilization for ambient logistics, and population-scale design as measurement infrastructure.
Sleep & circadian bioeconomy The science of consumer sleep sensing: photoplethysmography and why the LED is green, actigraphy's systematic bias, peripheral-versus-core temperature as a phase marker, melanopsin and the timing of light therapy, and the evidentiary gap between wellness devices and cleared diagnostics.
Sports bioeconomy The science of performance biomarker testing: lactate threshold as a production-clearance balance, creatine kinase as membrane-damage arithmetic, the contested reading of hormone ratios and athletic glucose curves, ferritin's double identity, and why serial trends outrank single panels.